By Jared S. Hopkins
Drugmakers breathed a sigh of relief Wednesday after President Trump didn't announce pharmaceutical tariffs.
Plus, language in the executive order indicated medicines were exempted from the reciprocal tariffs that Trump did announce.
Drugmakers were combing over the executive order to clarify the exemption language in the executive order and to make sure they won't be hit by any other tariff provisions, such as the 10% "baseline" tariff.
President Trump had said he was going to impose pharmaceutical tariffs at some point-a move that could have affected branded medicines imported from countries like Ireland as well as the many generic drugs made in India.
Shares of drugmakers in the U.S. and overseas varied in after-market trading, reflecting the lack of clarity.
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
April 02, 2025 18:03 ET (22:03 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.